Published in J Immunol on June 01, 2006
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 3.75
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 2.75
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood (2006) 2.58
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 2.46
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32
Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov (2012) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity (2008) 2.09
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest (2008) 2.06
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One (2008) 1.61
Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant (2013) 1.60
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 1.58
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med (2008) 1.54
AHR-mediated immunomodulation: the role of altered gene transcription. Biochem Pharmacol (2008) 1.46
IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol (2010) 1.46
Molecular mechanisms of treg-mediated T cell suppression. Front Immunol (2012) 1.41
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
The kynurenine system and immunoregulation. J Neural Transm (Vienna) (2011) 1.38
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann N Y Acad Sci (2010) 1.34
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol (2010) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. Toxicol Sci (2010) 1.25
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett (2008) 1.21
Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum (2009) 1.18
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One (2011) 1.11
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol (2008) 1.08
Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO. J Immunol (2008) 1.07
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest (2012) 1.05
Role of endogenous and induced regulatory T cells during infections. J Clin Immunol (2008) 1.03
High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun (2013) 1.03
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One (2012) 1.02
Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A (2010) 1.02
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front Immunol (2014) 1.01
Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology (2012) 1.01
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J Immunol (2011) 1.00
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer (2011) 0.98
An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One (2011) 0.97
IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog (2013) 0.96
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 0.96
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis (2009) 0.96
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica (2010) 0.96
Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest (2014) 0.95
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One (2013) 0.94
3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci (2011) 0.93
Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med (2009) 0.93
mTOR Links Environmental Signals to T Cell Fate Decisions. Front Immunol (2015) 0.93
Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol (2013) 0.92
Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 0.92
Evidence that eukaryotic translation elongation factor 1A (eEF1A) binds the Gcn2 protein C terminus and inhibits Gcn2 activity. J Biol Chem (2011) 0.91
CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J Clin Immunol (2009) 0.91
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Plasmacytoid dendritic cells in HIV infection. Adv Exp Med Biol (2013) 0.90
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLoS One (2015) 0.90
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer (2016) 0.90
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection. J Immunol (2011) 0.90
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer (2015) 0.90
Mechanisms of tolerance and allergic sensitization in the airways and the lungs. Curr Opin Immunol (2010) 0.90
Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect Immun (2008) 0.89
Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome. PLoS One (2011) 0.89
GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell Biol (2013) 0.89
Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest Ophthalmol Vis Sci (2009) 0.89
Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol (2010) 0.88
Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One (2014) 0.88
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Dendritic cell subsets in type 1 diabetes: friend or foe? Front Immunol (2013) 0.88
The role of placental tryptophan catabolism. Front Immunol (2014) 0.88
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet (2007) 5.68
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol (2002) 5.36
IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 4.54
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature (2008) 4.28
Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A (2003) 3.75
Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol (2004) 3.57
The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol (2002) 3.22
Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 3.18
Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol (2003) 3.01
Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet (2006) 2.95
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol (2004) 2.90
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 2.78
The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab (2007) 2.76
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med (2008) 2.62
CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity (2003) 2.59
Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science (2005) 2.51
Translational control and the unfolded protein response. Antioxid Redox Signal (2007) 2.47
TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell (2006) 2.46
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol (2007) 2.44
Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity (2010) 2.44
Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med (2003) 2.40
Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest (2003) 2.37
Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci (2013) 2.35
T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity (2009) 2.34
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol (2002) 2.32
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21
PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab (2006) 2.21
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med (2007) 2.08
Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J Biol Chem (2004) 2.00
S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta (2008) 1.97
Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol (2004) 1.86
Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol (2002) 1.83
Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity (2002) 1.74
Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med (2005) 1.72
Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem (2010) 1.72
Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol (2004) 1.69
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. Trends Microbiol (2006) 1.68